Bretaris Jenuair
Instructions for use:
- 1. Release form and composition
- 2. Indications for use
- 3. Contraindications
- 4. Method of application and dosage
- 5. Side effects
- 6. Special instructions
- 7. Drug interactions
- 8. Terms and conditions of storage
Prices in online pharmacies:
from 599 rub.
Buy
Bretaris Jenueir is a m-cholinergic receptor blocker, bronchodilator.
Release form and composition
Dosage form - dosed powder for inhalation: finely dispersed, free-flowing mass of almost white or white color, without visible foreign particles or conglomerates (in an inhaler, in a laminated package 1 inhaler: 30 doses each, in a cardboard box 1 package; 60 doses each, in a cardboard box 1 or 3 bags).
1 dose of powder contains:
- active substance: aclidinium bromide - 0.375 mg, which is equivalent to 0.322 mg of aclidinium;
- auxiliary component: lactose monohydrate.
Indications for use
Bretaris Jenueira is indicated as a supportive bronchodilator therapy in adults to relieve symptoms of chronic obstructive pulmonary disease (COPD).
Contraindications
- age up to 18 years;
- bronchial asthma;
- lactase deficiency, galactose intolerance, glucose-galactose malabsorption syndrome;
- hypersensitivity to lactose, atropine and its derivatives (oxitropium, ipratropium, tiotropium), aclidinium bromide.
Method of administration and dosage
The drug is intended for inhalation use.
After opening the package with the inhaler, before using it for the first time, remove the protective cap (slightly squeezing the arrows on each side and pulling outward) and make sure that nothing is blocking the mouthpiece.
While holding the inhaler in a horizontal position, point the mouthpiece towards you, so that the green button is facing straight up.
To prepare the drug for inhalation, press and release the green button. If the color control window turns green, the dose is ready to receive, if the window remains red, press and release the green button again.
Do not hold down the green button!
Exhaling completely, you should tightly clasp the mouthpiece of the inhaler with your lips and take a strong deep breath. Inspiratory depth and strength must ensure delivery of the drug to the lungs.
A clicking sound during inhalation means that the inhalation has been performed correctly, but you should not interrupt the inhalation immediately after the click, since the dose may not be complete.
After removing the inhaler from the mouth, breath must be held as long as possible and exhaled slowly through the nose.
Note: in some patients, when inhaling the drug, a slight sweetish or bitter taste may appear. The presence or absence of this effect is individual in nature and is not a reason for taking an additional dose.
If the color control window remains green, inhale strongly and deeply through the mouthpiece again. If the control window turns red after the procedure, this is a confirmation that the patient has taken the full dose. After inhalation, you must immediately put on a protective cap on the mouthpiece.
Note: the reason for maintaining the green color of the control window after inhalation may be an incorrect inhalation or a holding down the green button of the inhaler. Before each inhalation, make sure that the green button is released after loading the drug!
When prescribing Bretaris Jenueir, the physician must ensure that the patient is using the inhaler correctly.
Recommended dosage: 1 inhalation (or 0.322 mg of aclidinium) 2 times a day.
If you skip taking the next dose, you can only take it if it does not coincide in time with the next dose.
It is not required to adjust the dose in elderly patients with impaired renal or hepatic function.
The inhaler contains 30 or 60 doses and is equipped with a special indicator indicating the approximate number of doses remaining. When a tape with red stripes appears, you need to take care of purchasing a new inhaler, as this indicates the approach of the last dose.
Replacement of the inhaler is required if its body is damaged or the cap is lost. There is no need to clean the inhaler, if necessary, the outside of the mouthpiece can be wiped with a dry cloth or paper towel.
Do not use water to clean the inhaler, as this can spoil the quality of the drug.
When the number "0" appears on the dose indicator, the use of the doses remaining in the inhaler must be continued until the green button locks in the middle position and returns to the upper position. This means that the powder in the inhaler has run out. After taking the last dose, the patient starts using the new inhaler.
Side effects
- parasitic and infectious pathologies: often - nasopharyngitis, sinusitis;
- gastrointestinal tract: often - diarrhea; infrequently - stomatitis, dryness of the oral mucosa;
- respiratory system, chest and mediastinal organs: often - cough; infrequently - dysphonia;
- cardiovascular system: infrequently - palpitations, tachycardia;
- nervous system: often - headache; infrequently - dizziness;
- organ of vision: infrequently - blurred vision;
- dermatological reactions: infrequently - itching, rash;
- immune system: rarely - hypersensitivity reactions; frequency unknown - angioedema;
- urinary system: infrequently - urinary retention.
special instructions
When paradoxical bronchospasm appears while using the drug, therapy should be discontinued.
Aclidinium bromide is not an emergency treatment for COPD. Therefore, if the severity of the symptoms of the disease changes and the need arises for additional emergency treatment, it is necessary to re-evaluate the patient's condition and the appropriateness of using Bretaris Jenueir.
Due to the anticholinergic effect, the drug should be prescribed with caution in case of unstable angina pectoris, hospitalization for heart failure of III and IV functional classes according to the NYHA classification (New York Heart Association) in the previous 12 months, newly diagnosed arrhythmias in the previous 3 months, within 6 - months after myocardial infarction, patients with angle-closure glaucoma, bladder neck obstruction, prostatic hyperplasia.
Patients should be informed about the symptoms of an acute attack of angle-closure glaucoma, about the need to stop using inhalations if they appear and immediately consult a doctor.
Dryness of the oral mucosa can cause tooth decay over time.
The appointment of Bretaris Jenueir to patients under the age of 40 can only be made if there is a spirometric confirmation of the diagnosis of COPD.
Due to the risk of side effects (dizziness, headache, blurred vision), care should be taken when driving vehicles and mechanisms.
Drug interactions
Simultaneous use with other m-cholinergic receptor blockers is not recommended.
Possible combination with sympathomimetics, bronchodilators, methylxanthines, inhaled or oral glucocorticosteroids used to treat COPD.
In addition, the use of concomitant therapy with drugs that are substrates of P-glycoprotein or metabolizable cytochrome P 450 (CYP450) isoenzymes and esterases is shown.
Terms and conditions of storage
Keep out of the reach of children.
Store at temperatures up to 25 ° C.
Shelf life - 2 years, after opening the package - 3 months.
Bretaris Jenueir: prices in online pharmacies
|
Drug name Price Pharmacy |
|
Bretaris Jenueir 322 mcg / dose 60 doses powder for inhalation dosed 1 pc. RUB 599 Buy |
Information about the drug is generalized, provided for informational purposes only and does not replace the official instructions. Self-medication is hazardous to health!
